Gain Therapeutics Announces Cash Runway Into Q2 2027; Phase 2 Start in Q3 2026

What Happened

• On July 16, 2026 Gain Therapeutics, Inc. (GANX) issued a press release and shareholder letter and filed an 8‑K announcing that its current cash and cash equivalents are anticipated to fund the Company’s operations into the second quarter of 2027 based on current operating plans. The company said it expects to complete its Phase 1b open‑label extension in October 2026 and to initiate a Phase 2 clinical study during the third quarter of 2026.

Key Details

• Filing date: July 16, 2026 (Form 8‑K, Item 8.01 — Other Events).
• Cash runway: anticipated to cover operations into Q2 2027, based on current plans.
• Clinical timeline: Phase 1b open‑label extension completion targeted for October 2026; Phase 2 initiation targeted for Q3 2026.
• Forward‑looking caution: statements are qualified by the company’s cautionary note and risks described in its Form 10‑K for the year ended December 31, 2025.

Why It Matters

• For investors, the announcement provides a near‑term funding timeline (cash runway into Q2 2027) and concrete clinical milestones (Phase 1b completion and Phase 2 start) that can affect development progress and capital needs.
• These are forward‑looking targets based on current plans and subject to risks; actual timing and cash needs may change. The company refers investors to its 2025 Form 10‑K for risk factors and disclaims any obligation to update forward‑looking statements.